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Abstract
Background: Homozygous inactivating GCK mutations have been repeatedly re-
ported to cause severe hyperglycemia, presenting as permanent neonatal diabetes 
mellitus (PNDM). Conversely, only two cases of GCK homozygous mutations caus-
ing mild hyperglycemia have been so far described. We here report a novel GCK 
mutation (c.1116G>C, p.E372D), in a family with one homozygous member show-
ing mild hyperglycemia.
Methods: GCK mutational screening was carried out by Sanger sequencing. 
Computational analyses to investigate pathogenicity and molecular dynamics (MD) 
were performed for GCK‐E372D and for previously described homozygous muta-
tions associated with mild (n = 2) or severe (n = 1) hyperglycemia, used as references.
Results: Of four mildly hyperglycemic family‐members, three were heterozygous 
and one, diagnosed in the adulthood, was homozygous for GCK‐E372D. Two nondi-
abetic family members carried no mutations. Fasting glucose (p = 0.016) and HbA1c 
(p = 0.035) correlated with the number of mutated alleles (0–2).
In‐silico predicted pathogenicity was not correlated with the four mutations’ sever-
ity. At MD, GCK‐E372D conferred protein structure flexibility intermediate between 
mild and severe GCK mutations.
Conclusions: We present the third case of homozygous GCK mutations associated 
with mild hyperglycemia, rather than PNDM. Our in‐silico analyses support previous 
evidences suggesting that protein stability plays a role in determining clinical sever-
ity of GCK mutations.
K E Y W O R D S
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1 |  BACKGROUND
Glucokinase (GCK, OMIM 138079) catalyzes the phosphor-
ylation of glucose to glucose‐6‐phosphate, the first step in 
glucose metabolism. In pancreatic beta cells, GCK plays a 
role on insulin secretion acting as a sensor of extracellular 
glucose concentration; accordingly, altered GCK function 
may affect glucose homeostasis causing either hyperglycemia 
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or hypoglycemia, depending on whether the enzymatic activ-
ity is reduced or increased, respectively (Osbak et al., 2009).
It is well established that heterozygous loss of function 
GCK mutations cause maturity‐onset diabetes of the young 
(MODY) also known as MODY2 (GCK‐MODY; OMIM 
entry #125851). This subtype of monogenic diabetes is char-
acterized by mild fasting hyperglycemia, with patients usually 
needing no pharmacological treatment and having a very low 
risk of chronic diabetic complications (Steele et al., 2014).
Conversely, homozygous inactivating mutations of GCK 
have been repeatedly reported (Bennett et al., 2011; Njølstad 
et al., 2001; Raimondo et al., 2014; Turkkahraman et al., 
2008) to cause permanent neonatal diabetes mellitus (PNDM; 
OMIM entry #606176). Unlike GCK‐related‐MODY, GCK‐
related‐PNDM is characterized by severe hyperglycemia.
This scenario was partly questioned by a recent study 
(Raimondo et al., 2014) reporting in white French Canadians 
two cases of homozygous GCK mutations causing a mild, 
childhood‐onset diabetes, rather than a severe, neonatal‐onset 
disease. More generally, this study was instrumental in high-
lighting that, according to their ability to affect protein stabil-
ity, homozygous GCK mutations cause a spectrum of glucose 
homeostasis abnormalities, ranging from very mild to severe 
hyperglycemia.
We here describe a new homozygous GCK missense 
mutation (c.1116G>C, p.E372D) causing in a white Italian 
woman, a mild form of diabetes diagnosed at 22 years of age, 
during pregnancy. To the best of our knowledge, this is the 
third case of homozygous GCK mutation associated to diabe-
tes occurring outside infancy.
2 |  METHODS
2.1 | Sequencing studies
Genomic DNA was extracted and GCK (RefSeq 
NM_000162.3) studied by direct Sanger sequencing and by 
a next generation sequencing (NGS) guided approach, as de-
scribed in Data S1.
2.2 | In‐silico studies
2.2.1 | Pathogenicity prediction
The impact of the four variants on GCK was assessed by six-
teen pathogenicity prediction software packages. See Data 
S1.
2.2.2 | Molecular dynamics simulation
The atomic model of the wild‐type GCK protein (GCK‐WT) 
in complex with a molecule of glucose was obtained from 
the Protein Data Bank (id:1V4S). GCK‐WT was mutated 
in‐silico through UCSC Chimera to introduce the variations 
of interest. The resulting models were subjected to Molecular 
Dynamics (MD) simulation, as previously described (Biagini 
et al., 2017) and reported in Data S1.
2.3 | Statistical analyses
Data on correlation between glucose or HbA1c levels and 
number of mutated alleles were evaluated by linear regres-
sion model and reported as Beta (β) value ± Standard Error 
(SE). A two sided p‐values < 0.05 were considered as sta-
tistically significant. Statistical analyses were performed by 
using R, version 3.3.3 (Team & RDC, 2017).
3 |  RESULTS
3.1 | Clinical data
A genetic counseling was asked for a 3‐years‐old boy, sub-
ject IV‐1 (family's pedigree is shown in Figure S1), whose 
blood glucose concentrations were 89 mg/dl and 213 mg/
dl at fasting and 2  hr after an oral glucose load, respec-
tively. He also had a prediabetes HbA1c level of 44 mmol/
mol (6.2%). Tests for antibodies against insulin, glutamic 
acid decarboxylase, and protein tyrosine phosphatase–like 
molecule IA‐2 were negative. Subject III‐2 (30‐years‐old) 
showed impaired fasting glucose (114 mg/dl) and a predia-
betes HbA1c level of 41  mmol/mol (5.9%) while in sub-
ject II‐3 (51‐years‐old), diabetes was diagnosed at 22 years 
during her first pregnancy. Since then, she was treated with 
metformin (discontinued at our Institution after genetic di-
agnosis was made). Her recent fasting glucose and HbA1c 
levels ranged 129–140 mg/dl and 44–54 mmol/mol (6.2%–
7.1%), respectively. Finally, in subject II‐2 (61‐years‐old) 
diabetes was diagnosed at 50 years; under continuous met-
formin treatment (as before, this was discontinued after 
genetic diagnosis), last fasting blood glucose concentra-
tion was 94  mg/dl while HbA1c level was 39  mmol/mol 
(5.7%), the prediabetes threshold. In addition, subjects 
III‐3 and IV‐2 showed normal fasting glucose levels, equal 
to 97  mg/dl and 87  mg/dl, respectively. HbA1c level in 
subject III‐3 was 37  mmol/mol (5.5%), while no HbA1c 
level was available for subject IV‐2. At Sanger sequencing, 
proband resulted heterozygous for a new GCK missense 
mutation c.1116G>C, p.E372D. No additional mutations 
were found in any of the additional 27 monogenic diabetes 
genes screened by custom targeted NGS panel. The same 
mutation was screened by Sanger sequencing in all fam-
ily members. Quite surprisingly, while subjects III‐2 and 
II‐2 were heterozygous, subject II‐3, the proband's paternal 
grandmother, turned out to be homozygous; no mutation 
was found in subject III‐3 and IV‐2. No information on 
consanguinity between subjects I‐1 and I‐2 was available. 
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Table 1 shows all these measurements as well as additional 
clinical features of the four affected members.
Of interest, a clear correlation was observed between both 
fasting glucose (β ± SE = 21.2 ± 6.7 mg/dl, p = 0.016) and 
HbA1c (β  ±  SE  =  0.8  ±  0.2%, p  =  0.035) levels and the 
number of mutated alleles (0–2) across the six family study 
members (Figure S2, panels a and b).
3.2 | In‐silico analyses
Our GCK‐E372D variant was analyzed in‐silico and com-
pared to previously described GCK homozygous mutations 
that were associated to a wide range of clinical severity and 
protein stability. In detail, the GCK‐H50D mutation, re-
ported to dramatically hamper protein stability and to cause 
a severe form of PNMD, was chosen as a reference severe 
mutation (Raimondo et al., 2014), while GCK‐D160N and 
GCK‐V226M, carried by mild hyperglycemic subjects and 
with mild impact on protein stability, were chosen as refer-
ence mild mutations (Raimondo et al., 2014).
3.2.1 | Pathogenicity prediction
GCK‐E372D was considered harmful by 11 out of 16 pre-
dictor tools, while GCK‐H50D, GCK‐D160N, and GCK‐
V226M were predicted harmful by 14, 14, and 15 predictors 
(Table S1), respectively. Clearly, no parallelism was ob-
served between predicted pathogenicity and clinical severity.
3.2.2 | MD simulation
The GCK molecule contains a small and a large domain, en-
veloping the glucose‐binding site. Amino acid residues 1–64 
and 206–439 belong to the large domain, while amino acid 
residues 72–201 and 445–465 belong to the small one. Amino 
acid residues 65–71, 202–205 and 440–444 form three loops 
connecting these two domains (Kamata, Mitsuya, Nishimura, 
Eiki, & Nagata, 2004).
The dynamics of GCK upon glucose binding, with the 
protein switching from an inactive (open) to an active (close) 
conformation (Kamata et al., 2004), was assessed in terms of 
Root‐Mean‐Square‐Deviation (RMSD, Data S1). Compared 
to GCK‐WT (Figure 1a, panel‐1), our novel GCK‐E372D 
mutation (Figure 1a, panel‐2) showed higher RMSD de-
viations; an even greater difference toward higher RMSD 
deviations was shown by the severe, PNMD‐related GCK‐
H50D mutation (Figure 1a, panel‐3). Conversely, the two 
mild, GCK‐D160N and GCK‐V226M mutations (Figure 1a, 
panel‐4 and panel‐5) showed lower RMSD deviation, as com-
pared to GCK‐WT. Mutual atomic motions were represented 
by Dynamic‐Cross‐Correlation‐Maps (DCCMs, Data S1). In 
GCK‐WT (Figure 1b, panel‐1), atoms in the small domain 
moved in an anticorrelated way with those in the large do-
main. Such anticorrelation was clearly increased in GCK‐
E372D (Figure 1b, panel‐2) and even more in GCK‐H50D 
(Figure 1b, panel‐3), while it was conserved, at least partly 
in GCK‐D160N and GCK‐V226M (Figure 1b, panel‐4 and 
panel‐5).
Finally, hierarchical clustering analysis of the binding 
pocket volume dynamics over time showed that, as compared 
to GCK‐WT, GCK‐E372D lies in between the two mild 
GCK‐D160N and GCK‐V226M and the severe, PNMD‐re-
lated GCK‐H50D mutations (Figure 2).
4 |  DISCUSSION
Homozygous inactivating mutations of GCK have been re-
peatedly reported to contribute to PNDM, with only two 
exceptions, described in 9 and 15  years old white French 
Canadians showing mild hyperglycemia totally superim-
posable to that observed in GCK‐related MODY conditions 
(Raimondo et al., 2014). We here describe a novel GCK mis-
sense mutation p.E372D that in an Italian family co‐segre-
gates with mild impairment of glucose homeostasis not only 
in heterozygous patients but also in the only homozygous 
family member who was diagnosed as diabetic in the adult 
life. Fasting glucose was below the threshold of diabetes 
diagnosis in all three heterozygous individuals and within 
the normal range in two of them. In addition, HbA1c level 
was in the range of prediabetes (ADA, 2019) in all of them. 
These results are fully compatible with previous reports in 
T A B L E  1  Clinical features of family members carrying the GCK (c.1116G<C, p.E372D) mutation
  Subject IV−1 Subject III−2 Subject II−3 Subject II−2
Gender (M/F) M M F F
Age at diagnosis of hyperglycemia 
(years)
3 30 22 50
BMI (kg/m2) 17.6 27.5 27.2 32.1
Fasting glucose (mg/dl) 86–89 114 129–140 96–94
HbA1c (mmol/mol) 44 41 44–54 39
Abbreviations: F, Female; M, Male.
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patients with GCK‐MODY (Chakera et al., 2015; McDonald 
& Ellard, 2015), although they may have also been partly 
influenced by the ongoing treatment with metformin that two 
of our cases were taking when referred to our Institute. It is 
worth noticing that in the proband, glucose level at 120 min 
at OGTT had a delta increase as compared to fasting level 
of 124 mg/dl that is much higher than what usually reported 
for GCK‐MODY patients. Interestingly, among our family 
members, a clear correlation between the number of mutated 
alleles and both fasting glucose and HbA1c levels was ob-
served (i.e., gene‐dose effect). To the best of our knowledge, 
this is the third example of GCK homozygous missense mu-
tation, which, rather than causing PNDM, causes a typical 
GCK‐related mild hyperglycemia.
F I G U R E  1  Molecular dynamics 
analysis. Panel a shows the backbone 
Root‐Mean‐Square‐Deviation (RMSD) 
of the native and mutant structures of the 
GCK protein. The blue, red, brown, violet, 
and yellow lines indicate the native GCK‐
WT, the GCK‐E372D, the GCK‐H50D, 
the GCK‐D160N, and the GCK‐V226M 
mutant structures, respectively. Panel b 
shows the Dynamic‐Cross‐Correlation‐
Maps (DCCMs); each matrix displays the 
long‐range interactions between the atoms 
forming the small and the large domain of 
GCK native and mutant proteins. Red to 
green peaks in the maps are indicative of 
strong to moderate positive correlation, dark 
to light blue peaks are indicative of strong 
to moderate anticorrelation between the 
indicated residue numbers
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To address the biological significance of our new muta-
tion and to compare it to previously reported GCK mutations 
showing a wide range of clinical severity and dysfunctional 
biological features (Raimondo et al., 2014), in‐silico analyses 
were carried out.
All GCK mutations analyzed by a composite score, com-
prising 16 distinct pathogenicity tools (Table S1), were pre-
dicted harmful, with no parallelism with disease severity.
Dynamics of GCK, carried out under conditions simu-
lating glucose binding, suggest that GCK‐E372D confers a 
more flexible structure as compared to GCK‐WT. Notably 
the severe, PNDM associated GCK‐H50D mutation, showed 
effects that, though toward the same directions, were much 
stronger than those of GCK‐E372D. Conversely, both mild 
GCK‐D160N and GCK‐V226M mutations induced opposite 
effects suggesting a less flexible, more stable GCK protein 
than GCK‐WT. In all, our in‐silico MD analyses, including 
also mutual atomic motions and hierarchical clustering anal-
ysis indicate that the novel GCK‐E372D mutation lies func-
tionally somewhere in between the mild GCK‐D160N and 
GCK‐V226M and the severe PNDM‐related GCK‐H50D 
mutations.
Previous in vitro experimental evidences suggested that 
the degree of GCK clinical severity is inversely related to 
protein stability (Raimondo et al., 2014). In fact, our pres-
ent in‐silico data are fully compatible with the previously re-
ported relative differences in protein stability among severe 
and mild GCK mutations (Raimondo et al., 2014). Within 
this frame, however, the increased flexibility showed by our 
novel GCK‐E372D mild mutation as compared to GCK‐WT 
suggests that mild GCK mutations, though more stable than 
severe mutations, are not necessarily characterized by abso-
lutely increased protein stability.
In conclusion, we here report the third evidence of a 
GCK homozygous mutation that, rather than causing PNDM, 
causes mild abnormalities of glucose homeostasis diagnosed 
out of infancy. Our present data reinforce the concept of ge-
netic heterogeneity in the subset of GCK‐related diabetes that 
may translate into a wide range of phenotypes, from the more 
extreme to intermediate ones. In‐silico analyses together with 
previous in vitro experimental data (Raimondo et al., 2014), 
support the idea that protein stability plays a role on mutation 
clinical severity.
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